(Q37774240)

23 August 2017

1 reference

title

Molecular therapy of breast cancer: progress and future directions (English)

1 reference

23 August 2017

1 reference

Sheng-Xiang Lin

1

0 references

author name string

Jiong Chen

2

1 reference

23 August 2017

Mausumi Mazumdar

3

1 reference

23 August 2017

Donald Poirier

4

1 reference

23 August 2017

Cheng Wang

5

1 reference

23 August 2017

Arezki Azzi

6

1 reference

23 August 2017

Ming Zhou

7

1 reference

23 August 2017

language of work or name

1 reference

20 July 2010

1 reference

Nature Reviews Endocrinology

23 August 2017

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

485-493

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2010.92

23 August 2017

exact match

0 references

cites work

Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

HER-2/neu Oncogene Characterization in Head and Neck Squamous Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Aromatase and intracrinology of estrogen in hormone-dependent tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

New development in intracrinology of breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Raloxifene, tamoxifen and vascular tone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The drug facts box: providing consumers with simple tabular data on drug benefit and harm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Enhancing the adjuvant treatment of hormone receptor positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Aromatase inhibitors for breast cancer prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Update of the BIG 1-98 Trial: where do we stand?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

NICE updates guidance on early and advanced breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Structural basis for androgen specificity and oestrogen synthesis in human aromatase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Importance of estrogen sulfates in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Aromatase and the breast: regulation and clinical aspects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The relationship between 17 beta-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The discovery and mechanism of action of letrozole

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

In situ production of sex steroids in human breast carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Potent inhibition of steroid sulfatase activity by 3-O-sulfamate 17alpha-benzyl(or 4'-tert-butylbenzyl)estra-1,3,5(10)-trienes: combination of two substituents at positions C3 and c17alpha of estradiol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Dual aromatase-steroid sulfatase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Steroid sulfatase: a new target for the endocrine therapy of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Structure of human estrone sulfatase suggests functional roles of membrane association

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Human Estrogenic 17β-Hydroxysteroid Dehydrogenase: Predominance of Estrone Reduction and Its Induction by NADPH

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17beta-hydroxysteroid dehydrogenase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent d

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Triple-negative/basal-like breast cancer: review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Basal-like breast cancer: a critical review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Refinement of breast cancer classification by molecular characterization of histological special types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Triple-negative breast cancer--current status and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Trastuzumab--mechanism of action and use in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Overview of tyrosine kinase inhibitors in clinical breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

MicroRNA gene expression deregulation in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

miR-21-mediated tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Crosstalk between IGF1R and estrogen receptor signaling in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Aromatase inhibitors and breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Infertility, ovulation induction treatments and the incidence of breast cancer--a historical prospective cohort of Israeli women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

Clinical application of the 70-gene profile: the MINDACT trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.92

The Hedgehog pathway is a possible therapeutic target for patients with estrogen receptor-negative breast cancer.

31 March 2020

1 reference

12 December 2020

Oestrogen-synthesising enzymes and breast cancer.

1 reference

12 December 2020

Selective estrogen receptor modulator

1 reference

12 December 2020

Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.

1 reference

12 December 2020

Clinical use of aromatase inhibitors in the treatment of breast cancers

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels

1 reference

12 December 2020

Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Involvement of microRNAs in breast cancer.

1 reference

12 December 2020

Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line

1 reference

12 December 2020

Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.

1 reference

12 December 2020

Extragonadal synthesis of sex steroids: intracrinology

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2010.92

1 reference

23 August 2017

1 reference